Partners in the seed financing included Thiel Capital, Bioverge, Sanford Biosciences and Christian Angermayer's Presight Capital.
Kevin Kalish has over 15 years' experience leading R and D, Program Management and Operations with Medtronic, Boston Scientific and Johnson and Johnson. Most recently he provided strategic leadership to the Transformative Solutions business unit at Medtronic.
He received his MBA from Boston College, BSE/MSE from UMass Lowell and is Program Management Professional certified.
EnClear Therapies is a Cambridge based biotechnology company developing neurology-focused, device-based systems that remove toxic proteins as therapies for the treatment of neurodegenerative diseases and provide closed loop delivery and monitoring of cerebrospinal fluids.
The company's first products will target improving the lives of patients with Amyotrophic Lateral Sclerosis and Progressive Supranuclear Palsy.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval